The ASCO Post (@ascopost) 's Twitter Profile
The ASCO Post

@ascopost

News and views from the world of clinical oncology and hematology

ID: 96994334

linkhttp://WWW.ASCOPOST.COM calendar_today15-12-2009 14:48:51

34,34K Tweet

61,61K Takipçi

4,4K Takip Edilen

The ASCO Post (@ascopost) 's Twitter Profile Photo
The ASCO Post
@ascopost

17 days ago

New in #PancreaticCancer: Adding tocilizumab to nab-paclitaxel + gemcitabine didn’t meet 6-mo OS goal, but improved 18-mo survival (27.1% vs 7%) and reduced muscle loss. More grade ≥3 AEs noted. #oncology #ASCO ascopost.com/news/may-2025/…

New in #PancreaticCancer: Adding tocilizumab to nab-paclitaxel + gemcitabine didn’t meet 6-mo OS goal, but improved 18-mo survival (27.1% vs 7%) and reduced muscle loss. More grade ≥3 AEs noted. #oncology #ASCO ascopost.com/news/may-2025/…